Companion and Complementary Diagnostics–Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non–Small Cell Lung Cancer
暂无分享,去创建一个
[1] B. Melosky. Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer , 2014, Front. Oncol..
[2] F. Hirsch,et al. Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? , 2016, Archives of pathology & laboratory medicine.
[3] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[4] Bert Vogelstein,et al. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies , 2006, Nature Biotechnology.
[5] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[6] The Development of the HercepTest™ — from Bench to Bedside , 2010, Molecular Diagnostics.
[7] A. Korman,et al. In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates , 2014, Cancer Immunology Research.
[8] O. Abdel-Rahman. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. , 2016, Critical reviews in oncology/hematology.
[9] R. Juergens,et al. Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer , 2017, Front. Oncol..
[10] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[11] Gideon Blumenthal,et al. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy , 2016, The oncologist.
[12] M. Aldarouish,et al. Trends and advances in tumor immunology and lung cancer immunotherapy , 2016, Journal of Experimental & Clinical Cancer Research.
[13] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[14] I. Shapira,et al. Immune checkpoint inhibitors in malignancies with mismatch repair deficiency: a review of the state of the current knowledge , 2017, Journal of Investigative Medicine.
[15] J. T. Jørgensen. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC , 2016, Expert review of molecular diagnostics.
[16] Keunchil Park,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.
[17] S. Gettinger,et al. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] E. Bernicker,et al. Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung. , 2017, Journal of oncology practice.
[19] D. Gandara,et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC , 2016 .
[20] J. T. Jørgensen. Clinical application of companion diagnostics. , 2015, Trends in molecular medicine.
[21] E. Diamandis,et al. Cancer immunotherapy: the beginning of the end of cancer? , 2016, BMC Medicine.
[22] F. Hirsch,et al. PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[23] M. Dolled-Filhart,et al. Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. , 2016, Archives of pathology & laboratory medicine.
[24] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[25] J. T. Jørgensen,et al. Companion diagnostics-a tool to improve pharmacotherapy. , 2016, Annals of translational medicine.
[26] C. Gridelli,et al. Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies , 2017, PloS one.
[27] Sofamor Danek,et al. SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED) , 2004 .
[28] J. T. Jørgensen. The importance of predictive biomarkers in oncology drug development , 2016, Expert review of molecular diagnostics.
[29] J. T. Jørgensen,et al. Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives. , 2016, Trends in cancer.
[30] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[31] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.